Graft versus host disease following transfusion of normal blood products to patients with malignancies
A patient undergoing treatment with cytotoxic chemotherapy for Hodgkin's disease developed graft versus host disease (GVHD) following a transfusion of packed red cells. This is the 28th reported patient with a malignancy who did not have a bone marrow transplant and developed GVHD after transfu...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 1987-11, Vol.36 (3), p.206-209 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 209 |
|---|---|
| container_issue | 3 |
| container_start_page | 206 |
| container_title | Journal of surgical oncology |
| container_volume | 36 |
| creator | Kessinger, Anne Armitage, James O. Klassen, Lynell W. Landmark, James D. Hayes, James M. Larsen, Arden E. Purtilo, David T. |
| description | A patient undergoing treatment with cytotoxic chemotherapy for Hodgkin's disease developed graft versus host disease (GVHD) following a transfusion of packed red cells. This is the 28th reported patient with a malignancy who did not have a bone marrow transplant and developed GVHD after transfusion of normal blood or blood products. All patients had received cytotoxic chemotherapy prior to acquiring GVHD. The underlying malignancies included lymphoma, acute leukemia, neuroblastoma, rhabdomyosarcoma, and glioblastoma. Twenty‐three of the 28 patients died of GVHD. The incidence of transfusion‐related GVHD in this patient population is low but the illness is often fatal as treatment is largely ineffective. Transfusion‐related GVHD can be prevented by irradiating all blood products with 1500 rad prior to administration. |
| doi_str_mv | 10.1002/jso.2930360311 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77839874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>754560485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4391-24f96988e5f9523b8395127d68a00e2d7e1f5684d2ce859afffe7e2ede3ada9b3</originalsourceid><addsrcrecordid>eNqFkc1vEzEQxS0EKqFw5YbkA2pPG-y1vbaPqKKhH6KVKOJoObvj1mWzDp7dhv73uEoUxAVOHml-73n0HiFvOZtzxuoP95jmtRVMNExw_ozMOLNNZZk1z8msAHUltWUvySvEe8aYtY08IAdC8MYoNiNhkX0Y6QNknJDeJRxpFxE8Ag2p79MmDrd0zH7AMGFMA02BDimvfE-XfUodXefUTe2IdEx07ccIQ5k3cbyjhYm3gx_aCPiavAi-R3izew_Jt9NPNyefq8urxdnJx8uqlcLyqpbBNtYYUMGqWiyNsIrXumuMZwzqTgMPqjGyq1swyvoQAmiooQPhO2-X4pAcbX3LWT8nwNGtIrbQ936ANKHTulgaLQt4_G9QSdUwaVQh51uyzQkxQ3DrHFc-PzrO3FMFrlTg_lRQBO921tNyBd0e32Ve9u93e4-t70N-igj3mJZWMiMKZrfYJvbw-J9P3fnXq79OqLbaiCP82mt9_uEaLbRy378s3PWNLOleXLsL8RtoLrBA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754560485</pqid></control><display><type>article</type><title>Graft versus host disease following transfusion of normal blood products to patients with malignancies</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Kessinger, Anne ; Armitage, James O. ; Klassen, Lynell W. ; Landmark, James D. ; Hayes, James M. ; Larsen, Arden E. ; Purtilo, David T.</creator><creatorcontrib>Kessinger, Anne ; Armitage, James O. ; Klassen, Lynell W. ; Landmark, James D. ; Hayes, James M. ; Larsen, Arden E. ; Purtilo, David T.</creatorcontrib><description>A patient undergoing treatment with cytotoxic chemotherapy for Hodgkin's disease developed graft versus host disease (GVHD) following a transfusion of packed red cells. This is the 28th reported patient with a malignancy who did not have a bone marrow transplant and developed GVHD after transfusion of normal blood or blood products. All patients had received cytotoxic chemotherapy prior to acquiring GVHD. The underlying malignancies included lymphoma, acute leukemia, neuroblastoma, rhabdomyosarcoma, and glioblastoma. Twenty‐three of the 28 patients died of GVHD. The incidence of transfusion‐related GVHD in this patient population is low but the illness is often fatal as treatment is largely ineffective. Transfusion‐related GVHD can be prevented by irradiating all blood products with 1500 rad prior to administration.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.2930360311</identifier><identifier>PMID: 3316850</identifier><identifier>CODEN: JSONAU</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Combined Modality Therapy ; Female ; Graft vs Host Disease - etiology ; GVHD ; HLA Antigens - analysis ; Hodgkin Disease - complications ; Hodgkin Disease - therapy ; Humans ; immunodeficiency ; Medical sciences ; Middle Aged ; transfusion ; Transfusion Reaction ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Journal of surgical oncology, 1987-11, Vol.36 (3), p.206-209</ispartof><rights>Copyright © 1987 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4391-24f96988e5f9523b8395127d68a00e2d7e1f5684d2ce859afffe7e2ede3ada9b3</citedby><cites>FETCH-LOGICAL-c4391-24f96988e5f9523b8395127d68a00e2d7e1f5684d2ce859afffe7e2ede3ada9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.2930360311$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.2930360311$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7494083$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3316850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kessinger, Anne</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Klassen, Lynell W.</creatorcontrib><creatorcontrib>Landmark, James D.</creatorcontrib><creatorcontrib>Hayes, James M.</creatorcontrib><creatorcontrib>Larsen, Arden E.</creatorcontrib><creatorcontrib>Purtilo, David T.</creatorcontrib><title>Graft versus host disease following transfusion of normal blood products to patients with malignancies</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>A patient undergoing treatment with cytotoxic chemotherapy for Hodgkin's disease developed graft versus host disease (GVHD) following a transfusion of packed red cells. This is the 28th reported patient with a malignancy who did not have a bone marrow transplant and developed GVHD after transfusion of normal blood or blood products. All patients had received cytotoxic chemotherapy prior to acquiring GVHD. The underlying malignancies included lymphoma, acute leukemia, neuroblastoma, rhabdomyosarcoma, and glioblastoma. Twenty‐three of the 28 patients died of GVHD. The incidence of transfusion‐related GVHD in this patient population is low but the illness is often fatal as treatment is largely ineffective. Transfusion‐related GVHD can be prevented by irradiating all blood products with 1500 rad prior to administration.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Graft vs Host Disease - etiology</subject><subject>GVHD</subject><subject>HLA Antigens - analysis</subject><subject>Hodgkin Disease - complications</subject><subject>Hodgkin Disease - therapy</subject><subject>Humans</subject><subject>immunodeficiency</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>transfusion</subject><subject>Transfusion Reaction</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1vEzEQxS0EKqFw5YbkA2pPG-y1vbaPqKKhH6KVKOJoObvj1mWzDp7dhv73uEoUxAVOHml-73n0HiFvOZtzxuoP95jmtRVMNExw_ozMOLNNZZk1z8msAHUltWUvySvEe8aYtY08IAdC8MYoNiNhkX0Y6QNknJDeJRxpFxE8Ag2p79MmDrd0zH7AMGFMA02BDimvfE-XfUodXefUTe2IdEx07ccIQ5k3cbyjhYm3gx_aCPiavAi-R3izew_Jt9NPNyefq8urxdnJx8uqlcLyqpbBNtYYUMGqWiyNsIrXumuMZwzqTgMPqjGyq1swyvoQAmiooQPhO2-X4pAcbX3LWT8nwNGtIrbQ936ANKHTulgaLQt4_G9QSdUwaVQh51uyzQkxQ3DrHFc-PzrO3FMFrlTg_lRQBO921tNyBd0e32Ve9u93e4-t70N-igj3mJZWMiMKZrfYJvbw-J9P3fnXq79OqLbaiCP82mt9_uEaLbRy378s3PWNLOleXLsL8RtoLrBA</recordid><startdate>198711</startdate><enddate>198711</enddate><creator>Kessinger, Anne</creator><creator>Armitage, James O.</creator><creator>Klassen, Lynell W.</creator><creator>Landmark, James D.</creator><creator>Hayes, James M.</creator><creator>Larsen, Arden E.</creator><creator>Purtilo, David T.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>198711</creationdate><title>Graft versus host disease following transfusion of normal blood products to patients with malignancies</title><author>Kessinger, Anne ; Armitage, James O. ; Klassen, Lynell W. ; Landmark, James D. ; Hayes, James M. ; Larsen, Arden E. ; Purtilo, David T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4391-24f96988e5f9523b8395127d68a00e2d7e1f5684d2ce859afffe7e2ede3ada9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Graft vs Host Disease - etiology</topic><topic>GVHD</topic><topic>HLA Antigens - analysis</topic><topic>Hodgkin Disease - complications</topic><topic>Hodgkin Disease - therapy</topic><topic>Humans</topic><topic>immunodeficiency</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>transfusion</topic><topic>Transfusion Reaction</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kessinger, Anne</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Klassen, Lynell W.</creatorcontrib><creatorcontrib>Landmark, James D.</creatorcontrib><creatorcontrib>Hayes, James M.</creatorcontrib><creatorcontrib>Larsen, Arden E.</creatorcontrib><creatorcontrib>Purtilo, David T.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kessinger, Anne</au><au>Armitage, James O.</au><au>Klassen, Lynell W.</au><au>Landmark, James D.</au><au>Hayes, James M.</au><au>Larsen, Arden E.</au><au>Purtilo, David T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Graft versus host disease following transfusion of normal blood products to patients with malignancies</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>1987-11</date><risdate>1987</risdate><volume>36</volume><issue>3</issue><spage>206</spage><epage>209</epage><pages>206-209</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><coden>JSONAU</coden><abstract>A patient undergoing treatment with cytotoxic chemotherapy for Hodgkin's disease developed graft versus host disease (GVHD) following a transfusion of packed red cells. This is the 28th reported patient with a malignancy who did not have a bone marrow transplant and developed GVHD after transfusion of normal blood or blood products. All patients had received cytotoxic chemotherapy prior to acquiring GVHD. The underlying malignancies included lymphoma, acute leukemia, neuroblastoma, rhabdomyosarcoma, and glioblastoma. Twenty‐three of the 28 patients died of GVHD. The incidence of transfusion‐related GVHD in this patient population is low but the illness is often fatal as treatment is largely ineffective. Transfusion‐related GVHD can be prevented by irradiating all blood products with 1500 rad prior to administration.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>3316850</pmid><doi>10.1002/jso.2930360311</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 1987-11, Vol.36 (3), p.206-209 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77839874 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Combined Modality Therapy Female Graft vs Host Disease - etiology GVHD HLA Antigens - analysis Hodgkin Disease - complications Hodgkin Disease - therapy Humans immunodeficiency Medical sciences Middle Aged transfusion Transfusion Reaction Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Graft versus host disease following transfusion of normal blood products to patients with malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A50%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Graft%20versus%20host%20disease%20following%20transfusion%20of%20normal%20blood%20products%20to%20patients%20with%20malignancies&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Kessinger,%20Anne&rft.date=1987-11&rft.volume=36&rft.issue=3&rft.spage=206&rft.epage=209&rft.pages=206-209&rft.issn=0022-4790&rft.eissn=1096-9098&rft.coden=JSONAU&rft_id=info:doi/10.1002/jso.2930360311&rft_dat=%3Cproquest_cross%3E754560485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=754560485&rft_id=info:pmid/3316850&rfr_iscdi=true |